Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$9.40 ▼ -7.14
(-43.17%)
MKT CAP: $63.3M • VOL: 242.1K
52W L $9 52W H $38
PTHS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $16.8M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $12.8M | — | — |
| Gross Margin % | 76.3% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$32.4M | -$7.6M | -$6.9M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$43.3M | -$8.0M | -$7.4M |
| EBITDA (Normalized) | -$32.4M | -$7.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$22.6M | -$5.8M | -$981.0K |
| Capital Expenditures (CapEx) | $99.0K | $0 | — |
| Free Cash Flow (FCF) | -$22.7M | -$5.8M | -$981.0K |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $18.0M | $513.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $38.9M | -$2.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PTHS.